GnRH Agonists in the Treatment of Fibroids

  • Ralph Philosophe


Uterine leiomyomas (fibroids) are the most common solid pelvic tumor in women. They are found clinically in approximately 25% of women, and pathological serial sectioning shows that their prevalence is even higher.1 Fibroids represent the most common indication for hysterectomy for benign disease in the United States.2,3


Obstet Gynecol GnRH Agonist Uterine Fibroid GnRH Receptor Uterine Leiomyoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94: 435–438.PubMedGoogle Scholar
  2. 2.
    Lee NC, Dicker RC, Rubin GL, Ory HW. Confirmation of the preoperative diagnoses for hysterectomy. Am J Obstet Gynecol 1984; 150: 283–287.PubMedGoogle Scholar
  3. 3.
    Easterday CL, Grimes DA, Riggs JA. Hysterectomy in the United States. Obstet Gynecol 1983; 62: 201–212.Google Scholar
  4. 4.
    Robins SL, Cotran RS. Leiomyomata (fibromyoma). In: The Pathogenic Basis of Disease. Philadelphia: W.B. Saunders Co., 1979: 1271.Google Scholar
  5. 5.
    Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand 1985; 64: 307.PubMedCrossRefGoogle Scholar
  6. 6.
    Sadan O, Vanidelekinge B, Van Gelderen CJ, Savage N, Becker PJ, Van Der Walt LA, Robinson M. Estrogen and progesterone receptor concentrations in leiomyomas and normal myometrium. Ann Clin Biochem 1987; 24: 263.PubMedGoogle Scholar
  7. 7.
    Pollow K, Sinnecker G, Boquoi E, Pollow B. In vitro conversion of estradiol 17ß into estrone in normal human myometrium and leiomyoma. J Clin Chem Clin Biochem 1978; 16: 493–502.PubMedGoogle Scholar
  8. 8.
    Otubu JA, Buttram VC, Besch NF, Besch PK. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982; 143: 130.PubMedGoogle Scholar
  9. 9.
    Maheux R, Lemay A, Merat P. Use of intra-nasal leuteinizing hormone-releasing hormone agonist in uterine leiomyomas. Fertil Steril 1987; 47: 229–233.PubMedGoogle Scholar
  10. 10.
    Deligdish L, Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol 1970; 23: 676–680.PubMedCrossRefGoogle Scholar
  11. 11.
    Berkeley AS, DeCherney AH, Polan ML. Abdominal myomectomy and subsequent fertility. Surg Gynecol Obstet 1983; 156: 319–322.PubMedGoogle Scholar
  12. 12.
    Dicker RC, Greenspan JR, Strauss LT, Cowart MR, Scully MJ, Peterson HB, DeStefano HB, Rubin AL, Ory HW. Complications of ab-dominal and vaginal hysterectomy among women of reproductive age in the United States. The collaborative review of sterilization. Am J Obstet Gynecol 1982; 144: 841–848.PubMedGoogle Scholar
  13. 13.
    Richards DH. Depression after hysterectomy. Lancet 1973; 2: 430–433.PubMedCrossRefGoogle Scholar
  14. 14.
    Buttram VC, Reiter RC. Uterine leiomyomata: Etiology, symptomatology and management. Fertil Steril 1981; 36: 433–445.PubMedGoogle Scholar
  15. 15.
    Stovall TG, Ling FW, Henry LC, Woodruff MR. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991; 164: 1420–1425.PubMedGoogle Scholar
  16. 16.
    Goldzieher JW, Macqueo M, Ricaud L, Aguilar JA, Canales E. Induction of degenerative changes in uterine myomas by high dosage progestin therapy. Am J Obstet Gynecol 1966; 96: 1078–1087.PubMedGoogle Scholar
  17. 17.
    DeCherney AH, Maheux R, Polan ML. A medical treatment for myomata uteri. Fertil Steril 1983; 39: 429–430.Google Scholar
  18. 18.
    Coutinho EM, Boulanger GA, Concalves MT. Regression of uterine leiomyomata after treatment with gestrinone, an antiestrogen, anti-progesterone. Am J Obstet Gynecol 1986; 155: 761–767.PubMedGoogle Scholar
  19. 19.Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives. Br Med J 1986; 293: 359–362.CrossRefGoogle Scholar
  20. 20.
    Murphy AA, Kettel LM, Morales A, Yen SSC. Response of uterine fibroids to the antipro- gesterone RU 486. A pilot study. Abstract 071, AFS, Orlando, Florida 1991.Google Scholar
  21. 21.
    Baird DT, Bramley TA, Hawkins TA, Lumsden MA, West CP. Effect of treatment with GnRH analogue zoladex on binding of estradiol, progesterone and epidermal growth factor to uterine fibromyomata.Google Scholar
  22. 22.
    Lumsden MA, West CP, Bramley T, Rumgay L, Baird DT. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypoestrogenic by continuous administration of LH RH agonist. Br J Obstet Gynec 1988; 95: 1299–1304.CrossRefGoogle Scholar
  23. 23.
    Wiznitzer A, Marbach M, Hazum E, et al. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Comm 1988; 152: 1326.PubMedCrossRefGoogle Scholar
  24. 24.
    Rein MS, Friedman AJ, Pandian MR, Heffner LJ. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol 1990; 76: 388–394.PubMedGoogle Scholar
  25. 25.
    Resnik R, Killam AP, Battaglia FC, Makowski EL, Meschia G. The stimulation of uterine blood flow by various estrogens. Endocrinology 1974; 94: 1192–1196.PubMedCrossRefGoogle Scholar
  26. 26.
    Matta WHM, Stabile I, Shaw RW, Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist buserelin. Fertil Steril 1988; 49: 1083–1085.PubMedGoogle Scholar
  27. 27.
    Zawin M, McCarthy S, Scoutt L, Lange R, Lavy G, Vulte J, Comite F. Monitoring therapy with a gonadotropin-releasing hormone analog: Utility of MR imaging. Radiology 1990; 175: 503–506.Google Scholar
  28. 28.
    Benagiano G, Morini A, Abbondante A, et al. Sequential GnRH analogue (buserelin)— medroxyprogesterone acetate MPA treatment of uterine leiomyomata. In: Vickery BH, Lunenfeld B, eds. GnRH Analogues in Cancer and Human Reproduction. Lancaster: MTP Press.Google Scholar
  29. 29.
    Loumaye E, Naor Z, Catt KJ. Binding affinity and biological activity of gonadotropin-releasing hormone agonists in isolated pituitary cells. Endocrinology 1982; 111: 730–736.PubMedCrossRefGoogle Scholar
  30. 30.
    Fraser HM. LHRH analogues: Their clinical physiology and delivery systems. In: Healy DL, ed., Balliere’s Clinical Obstetrics and Gyne-cology—International Practice and Research. Anti-Hormones in Clinical Gynecology. Vol 2. London: Balliere Tindall, 1988: 639.Google Scholar
  31. 31.
    Friendman AJ, Barbieri RL, Benacerraf BR, Schiff I. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril 1987; 48: 560–564.Google Scholar
  32. 32.
    Vollenhoven BJ, Shekleton P, McDonald J, Healy DL. Clinical predictors for buserelin acetate treatment of uterine fibroids: A pro-spective study of 40 women. Fertil Steril 1990; 54: 1032–1038.PubMedGoogle Scholar
  33. 33.
    West CP, Lumsden MA, Lawson S, Williamson J, Baird DT. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): A leuteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 48: 45–51.PubMedGoogle Scholar
  34. 34.
    Van der Spuy ZM, Fieggan AG, Wood MJA, Pienaar CA. The short-term use of luteinizing hormone-releasing hormone analogues in uterine fibroids. Horm Res 989;32(Suppl 1 ): 137–140.Google Scholar
  35. 35.
    Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas ATA. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma; a pilot study. Am J Obstet Gyn 1985; 152: 1034–1038.Google Scholar
  36. 36.
    Kessel B, Liu J, Mortola J, Berga S, Yen SSC. Treatment of uterine fibroids with agonist analogs of gonadotropin-releasing hormone. Fertil Steril 1988; 49: 538–541.PubMedGoogle Scholar
  37. 37.
    Collins RL. Treatment of symptomatic leiomyomata uteri with a long acting gonadotropin- releasing hormone agonist: Long-term follow- up. Gynecol Endocrinol (Suppl 1) 1988; 2: 89.Google Scholar
  38. 38.
    Andreyko JL, Blumenfeld Z, Marshall LA, Monroe SE, Hricak H, Jaffe RB. Use of an agonist analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: Assessment by magnetic resonance imaging. Am J Obstet Gynecol 1988; 158: 903–910.PubMedGoogle Scholar
  39. 39.
    Van Leusden HAIM. Triptorelin to prevent hysterectomy in patients with leiomyomas. Lancet 1988; 2: 508–519.PubMedCrossRefGoogle Scholar
  40. 40.
    Benagiano G, Primiero F, Morini A, Isidori C, Addi G, Tunner G. Multimodal pharmacological approach to the treatment of leiomyomata uteri. Gynecol Endocrinol (Suppl 2 ) 1988; 2: 50Google Scholar
  41. 41.
    Matta WHM, Shaw RW, Nye M. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynecol 1989; 96: 200–206.CrossRefGoogle Scholar
  42. 42.
    Williams IA, Shaw RW. Effect of Nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol 1990; 34: 111–117.PubMedCrossRefGoogle Scholar
  43. 43.
    Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: A double-blind, placebo-controlled, multicenter study. Obstet Gynecol 1991; 77: 720–725.PubMedGoogle Scholar
  44. 44.
    Meyer WR, Mayer AR, Diamond WP, et al. Unsuspected leiomyosarcoma: Treatment with a gonadotropin releasing hormone analogue. Obstet Gynecol 1990; 75: 529.PubMedGoogle Scholar
  45. 45.
    Benagiano A, Morini A, Aleandri V, Piccinno F, Primiero FM, Abbondante A, Elkind-Hirsch K. Sequential GnRH superagonist and medroxy-progesterone acetate treatment of uterine leiomyomata. Int J Obstet Gynecol 1990; 33: 333–343.CrossRefGoogle Scholar
  46. 46.
    Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention trial results. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351.CrossRefGoogle Scholar
  47. 47.
    Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47–51.PubMedGoogle Scholar
  48. 48.
    Matta WH, Shaw RW, Hesp R, Katz D. Hypogonadism induced by luteinizing hormone releasing hormone analogues: Effects on bone density in premenopausal women. Br Med J 1987; 294: 1523.CrossRefGoogle Scholar
  49. 49.
    Dodin S, Lemay A, Maheux R, Dumont M, Turcot-Lemay L. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991; 77: 410.PubMedGoogle Scholar
  50. 50.
    Van Leusden HAIM, Dogterom AA. Rapid reduction of uterine leiomyomas with montly injections of △-trp-GnRH. Gynecol Endocrinol 1988; 2: 45 – 51.PubMedCrossRefGoogle Scholar
  51. 51.
    Comite F, Jensen P. Bone density changes associated with GnRH analogues. International Symposium on GnRH Analogues in Cancer and Human Reproduction. Geneva, Switzerland, Feb 1988.Google Scholar
  52. 52.
    Comite F, Jensen P, Lewis A, et al. GnRH analog therapy in endometriosis: Impact on bone mass. Society for Gynecologic Investigation Atlanta, IGA, March No. 112, 1987.Google Scholar
  53. 53.
    Tummon IA, Ali A, Pepping ME, Radwanska E, Binor Z, Dmowski WP. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril 1988; 49: 792–796.PubMedGoogle Scholar
  54. 54.
    Bianchi G, Costantini S, Anserini P, Rovetta G, Monteforte P, Menada MV, Faga L, DeCecco L. Effects of gonadotropin-releasing hormone agonist on uterine fibroids and bone density. Maturitas 1989; 11: 179–185.PubMedCrossRefGoogle Scholar
  55. 55.
    Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: Effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989; 52: 21 – 26.PubMedGoogle Scholar
  56. 56.
    Devogelaer JP, Huaux JP, Donnez J, et al. Differential effects of the GnRH agonist buserelin on the axial and the appendicular skeleton at different scanning sites. Preferential loss of trabecular bone. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Proceedings of the International Symposium on Osteoporosis. Viborg: Norhaven Bogtrykkeri, p. 588.Google Scholar
  57. 56b.
    Devogelaer JP, De Deuxchaisnes CN, Donnez J, Thomas K. LHRH analogues and bone loss (letter). Lancet 1987; 1: 1498.PubMedCrossRefGoogle Scholar
  58. 57.
    Johansen JS, Riis BJ, Hassager C, Moer M, Jacobson J, Christiansen C. The effect of gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701–706.PubMedCrossRefGoogle Scholar
  59. 58.
    Matta WHM, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypoestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol 1988;29:45 –51.Google Scholar
  60. 59.
    Lumsden MA, West CP, Baird DT. Goserelin therapy before surgery for uterine fibroids (letter). Lancet 1987; 1: 36–37.PubMedCrossRefGoogle Scholar
  61. 60.
    Friedman AJ, Rein MS, Harrison-Atlas D, Garfield JM, Doubilet PM. A randomized, placebo controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril 1989; 52: 728–733.PubMedGoogle Scholar
  62. 61.
    Healy DL, Lawson SR, Abbott M, Baird DT, Fraser HM. Toward removing uterine fibroids without surgery: Subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. J Clin Endocrinol Metab 1986; 63: 619–625.PubMedCrossRefGoogle Scholar
  63. 62.
    Dubuisson JB, Mandlebrot L, Lecuru F, Aubriot FX, Foulot H, Mouly M. Myomectomy by laparoscopy: A preliminary report of 43 cases. Fertil Steril 1991; 56: 827–830.PubMedGoogle Scholar
  64. 63.
    Hsueh AJW, Peck EJ, Clark JH. Progesterone antagonism of the estrogen receptor and estrogen induced uterine growth. Nature 1975; 254: 337–339.PubMedCrossRefGoogle Scholar
  65. 64.
    Benagiano G, Morini A, Aleandri V, Piccinno F, Angelini R, Goldzieher JW. Sequential buserelin-medroxyprogesterone acetate treatment of leimyomata uteri. In: Brosens I, Jacobs HS, Runnebaum B, eds. LHRH Analogues in Gynecology. New Jersey: The Parthenon Publishing Group, 1990.Google Scholar
  66. 65.
    Friedman AJ, Barbieri RL, Doubilet PM, Fine C, Schiff I. A randomized, double-blind trial of gonadotropin-releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404–409.PubMedGoogle Scholar
  67. 66.
    Maheux R. The use of LHRH analogues in the treatment of leiomyoma uteri. In: Brosens I, Jacobs HS, Runnebaum B, eds. LHRH Analogues in Gynecology. New Jersey: The Parthenon Publishing Group, 1990.Google Scholar
  68. 67.
    Friedman AJ. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: A pilot study. Fertil Steril 1989; 51: 526–528.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1993

Authors and Affiliations

  • Ralph Philosophe

There are no affiliations available

Personalised recommendations